1043-3155 Pediatr Neurol Briefs pedneurbriefs Pediatr Neurol Briefs Pediatric Neurology Briefs Pediatr Neurol Briefs 2166-6482 1043-3155 2166-3155 Pediatric Neurology Briefs Publishers Chicago, IL, USA PNB-6-52-b 10.15844/pedneurbriefs-6-7-6 Anticonvulsant Drugs Neurology Pediatrics Nervous System Diseases Child Development Brain Diseases Neurosurgery Child Infant Chewable Versus Regular Carbamazepine http://orcid.org/0000-0002-0173-7931 Millichap J. Gordon MD 1 2 * Division of Neurology, Children's Memorial Hospital, Chicago, IL Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL Correspondence: Dr. J. Gordon Millichap, E-mail: jgmillichap@northwestern.edu 07 1992 01 07 2016 6 7 52 53 Copyright: © 1992 The Author(s) 1992 This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy

A comparison of chewable and regular carbamazepine (CBZ tablets) in 44 children receiving chronic CBZ monotherapy is reported from the IWK Children’s Hospital, Halifax, Nova Scotia.

 Chewable Regular Carbamazepine Pharmacokinetics

A comparison of chewable and regular carbamazepine (CBZ tablets) in 44 children receiving chronic CBZ monotherapy is reported from the IWK Children’s Hospital, Halifax, Nova Scotia. Weekly levels showed no consistent differences between the 1 month on chewable CBZ and on regular CBZ. Seizure control and rates of reported side effects were similar in the 2 periods. Chewable CBZ produced higher peak CBZ levels in 5 patients and a similar number had higher peaks with regular CBZ. [1]

COMMENT. Chewable and regular CBZ appear to have similar pharmacokinetics but individual patients may show some differences and those with peak level side effects using one form of CBZ should receive the alternative form of tablet.

A therapeutic bioequivalency study of brand name versus generic carbamazepine in 40 epileptic patients studied at the Bowman Gray School of Medicine, Winston-Salem, NC showed that both performed equally well in clinical efficacy and bioequivalency. [2]

 Camfield P Hwang P Camfield C Fraser A Soldin S al-Quadah AK The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy Can J Neurol Sci 1992 May 19 2 204 207 1623447 Oles KS Penry JK Smith LD Anderson RL Dean JC Riela AR Therapeutic bioequivalency study of brand name versus generic carbamazepine Neurology 1992 Jun 42 6 1147 1153 10.1212/WNL.42.6.1147 1603340